ArticleEuropean journal of medical research2025
Cholestasis as a complication in Kawasaki disease: an atypical clinical presentation.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Metabolic reprogramming rewires aberrant immune responses to drive endothelial dysfunction in Kawasaki disease: a narrative review.Translational pediatrics · 2026Review
- Extracriteria manifestations in Kawasaki disease: coronary threat or diagnostic pitfall?European journal of pediatrics · 2026Article
- Hepatobiliary involvement in Kawasaki disease: from cholestatic hepatitis to the hepatic vascular-biliary unit hypothesis-a state-of-the-art review.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCholestasis is an uncommon complication in Kawasaki disease (KD) that impacts the digestive system. This study aimed to examine the clinical characteristics and associated risk factors of KD complicated by cholestasis.
methodsAmong the 3026 KD patients admitted to Yuying Children's Hospital, affiliated with Wenzhou Medical University, from January 1, 2008, to December 31, 2020, all 72 children with cholestasis were included in the study. We performed a comprehensive analysis of the clinical characteristics, prognosis, and potential risk factors associated with KD patients presenting with cholestasis.
resultsAll 72 patients (median age: 34.1 months; 52.8% male) met the diagnostic criteria for cholestatic hepatitis. The mean duration of hospitalization was 10 days. Clinically, the incidence of limb edema and cervical lymphadenitis was relatively low. Pre-treatment assessments of liver function revealed significantly elevated levels of alanine aminotransferase, aspartate aminotransferase, and γ-glutamyl transpeptidase, with median values of 227 U/L, 102 U/L, and 220 U/L, respectively. Abdominal ultrasonography indicated an increased incidence of cholecystitis (12.5%) and hepatosplenomegaly (32.9%), in the absence of gallstones. Additionally, patients demonstrated an increased likelihood of systemic involvement, including pancreatitis and aseptic pyuria, alongside significantly elevated inflammatory markers such as C-reactive protein (CRP), white blood cell count (WBC), and neutrophil levels. All patients received treatment with intravenous immunoglobulin (IVIG) and aspirin, leading to the normalization of liver function indicators within one week. In this study, 25.0% of the patients demonstrated resistance to IVIG therapy, with 2 cases experiencing acute pancreatitis and shock. Furthermore, 25 patients developed coronary artery lesions, which resolved over a 32-month follow-up period as assessed by cardiac ultrasound.
conclusionWhen KD is complicated by cholestasis, it impacts the liver and bile ducts, leading to liver damage, cholecystitis, and jaundice, while also intensifying systemic inflammatory responses and increasing the likelihood of additional systemic involvements. Despite these complications, the prognosis is generally favorable; however, there is an associated elevated risk of resistance to IVIG therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.